Notice of Proposed Sale · 144

Travere Therapeutics, Inc.

TVTXNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 18, 2026Accepted Aug 18, 2026, 4:24 PM EDTFiling CIK 1123343Accession 0001950047-26-008327

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: TRAVERE THERAPEUTICS, INC.
Issuer CIK: 0001438533
SEC file number: 001-36257
Phone: 8889697879
Person for whose account securities are to be sold: GARY LYONS
Relationships to issuer: Director
Street: 3611 Valley Centre Drive, Suite 300
City: San Diego
State / country code: CA
Postal code: 92130

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	5,000	317,650.00	94,261,082	08/18/2026	NASDAQ	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	08/18/2026	Exercise of Stock Options	Issuer	5,000	N	08/18/2026	Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 1 reported row
Seller	Security	Sale date	Amount sold	Gross proceeds
10b5-1 Sales for GARY LYONS	Common	08/17/2026	5,000	315,985.50

Seller — prior-sale row 1, entry 1

Name: 10b5-1 Sales for GARY LYONS
Street: 3611 Valley Centre Drive, Suite 300
City: San Diego
State / country code: CA
Postal code: 92130

Prior-sale reporting

Nothing to report for the preceding three months: N

Notice signature

Notice date: 08/18/2026
Signed: /s/ Gary Lyons
Plan adoption dates: 05/18/2026

Company context

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent - that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow. For more information, visit travere.com.

Current securities

TVTXNASDAQ · EQUITY · Current

Get the free weekly BCS email.